Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Amgen sheds around 40 staffers amid continuing struggles
(2d)
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
(2d)
Merck stages expanded access to monthly HIV PrEP pill ahead of approval
(2d)
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
(2d)
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
(2d)
Chutes & Ladders—Biogen R&D vet gets in Formation
(3d)
Scancell to go public after winning reverse merger bid for troubled Neuphoria
(3d)
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
(3d)
Roche Diagnostics growth remains muted amid China headwinds
(3d)
Australian biopharma Clinuvel to shed up to 20% of workforce in move to US
(3d)
BioPharma Dive
Sanofi halts development of troubled immune drug in eczema
(2d)
Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myeloma
(2d)
Scribe secures $129M in a rare gene editing IPO
(3d)
FDA panel endorses broader use of certain peptides
(3d)
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
(3d)
Vertex was sole bidder in high-premium Crinetics acquisition
(4d)
GSK lung cancer drug gets speedy approval following $10.6B deal
(4d)
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
(4d)
Trump threatens tariffs on imported generic drugs
(4d)
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
(4d)
Endpoints News
Anthropic’s life science plans; Novartis CEO on China deals; and more
(1d)
Amgen shares new Tavneos analysis in effort to resolve FDA dispute
(2d)
Ipsen’s Bylvay fails key trial in children with rare liver disease
(2d)
Biogen’s Alzheimer’s data spur excitement, confusion about tau-targeting drugs
(2d)
Novo asks court to block Lilly ads; Merck strikes HIV PrEP deal
(2d)
CHMP recommends Minoryx’s ALD drug, rejects Zevra’s Meplyffa
(2d)
Michael Ehlers joins Formation Bio to lead R&D Black Diamond co-founder dies at 67
(2d)
Sanofi nixes Kymab-originated OX40L antibody in atopic dermatitis
(2d)
Gene editor Scribe starts second-half IPO spree with $129M listing
(2d)
FDA adcomm votes in favor of lifting restrictions on popular wellness peptide BPC-157
(3d)
BioSpace
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
(2d)
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
(2d)
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
(2d)
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
(2d)
Roche cans one Carmot obesity asset as another shows best-in-class potential
(2d)
BeOne commits $300M to US manufacturing expansion, creating 120 new jobs
(3d)
Lilly preps FDA run for ‘triple-G’ weight loss drug with Phase 3 data
(3d)
Roche's late stage pipeline "so full" CEO Schinecker not feeling pressure to add on
(3d)
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
(3d)
Nordic biotech’s next act: From fragmentation to global force
(3d)
STAT News
I led the FDA’s food safety and nutrition center. Here’s what people are missing about the cyclospora outbreak
(2d)
FDA advisory panel narrowly rejects compounding of one peptide, back another
(2d)
There are already more U.S. measles cases this year than in all of 2025
(2d)
Up and down the ladder: The latest comings and goings
(2d)
Fatal gene-editing trial in China raises ethics and oversight questions
(2d)
We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
(2d)
A new, separate outbreak of the diarrhea-causing parasite
(2d)
Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
(2d)
White House offers its science blueprint: More AI, less life sciences
(2d)
Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
(2d)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(1mo)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(1mo)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2mo)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(2mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(3mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(3mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(3mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(3mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(3mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(3mo)
Drug Channels
Direct-to-Patient: Transforming the Manufacturer Access Model
(2d)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(5d)
2025 Gross-to-Net Realities at Eight Top Drugmakers: The Net Pricing Drug Channel Emerges
(5d)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(1w)
Direct-to-Consumer Shouldn't Always Mean Direct-To-Mail-Order: Why Fulfillment Choice Matters
(1w)
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
(2w)
The 340B Program Hit $100 Billion in 2025: Has It Become Too Big to Reform?
(2w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(2w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(2w)
Medicare Embraces Site-Neutral Payments. Why Haven't Employers?
(2w)
European Biotechnology Magazine
CHMP backs Minoryx’s rare disease drug two years after rejection
(2d)
Sanofi drops eczema drug from $1.1B Kymab deal
(2d)
Iceland-based Synaptiq launches with Nobias’ rare disease drug
(2d)
Fresenius launches €200M healthcare venture fund
(3d)
Neurimmune turns future royalties into $425m pipeline cash
(3d)
OMEICOS takes repurposed drug directly into Phase 3
(4d)
Novartis drops Phase 2 radioligand therapy
(4d)
Immitra Bio raises CHF 2.4M for in-vivo gene editing
(5d)
Phinomics Brings a New Layer of Cancer Biology from the U.S. to Berlin
(5d)
Samsung Targets Swiss CDMO PolyPeptide in $1.8 Billion Deal
(5d)
Drug Hunter
zidebactam
(2d)
centanafadine
(3d)
thalidomide
(4d)
18F-florquinitau
(5d)
The NaV1.7 Disconnect: Pharmacologic Inhibition Does Not Recapitulate Genetic Loss
(6d)
Orum’s DACs Aim to Expand the Therapeutic Window of GSPT1 Degraders
(1w)
Emerging Strategies for GSPT1 Degradation
(1w)
nibrozetone
(2w)
zovegalisib (RLY-2608)
(2w)
Module 5, Section 3: Structure-Based Design
(2w)
Labiotech.EU
Munich’s biotech hub: Inside one of Europe’s leading life sciences ecosystems
(2d)
This nonprofit is building the ecosystem to cure epidermolysis bullosa
(2d)
Is an HIV cure possible? The future of HIV therapy
(4d)
Roche’s new gene sequencer on the market: where do current players stand?
(5d)
Inside one of Europe’s most advanced biotech innovation hubs
(5d)
Guinea worm: Why disease eradication is so rare
(6d)
How BIO-Europe is expanding beyond dealmaking in 2026
(1w)
Race for approval: biotechs accelerate bipolar disorder therapies
(2w)
Inside Takeda’s transformation: The pipeline strategy behind its next growth chapter
(2w)
End-to-end: Curia drives supply and scale for steroid and hormonal therapies
(2w)
Bio IT World
The Most Expensive AI Mistake in Biotech Isn’t a Hallucination, It’s a Process Failure
(2d)
In Vivo CRISPR Therapy is One Step Closer to the Clinic
(3d)
Different Teams, Same Problem
(4d)
Winning Best of Show Again: A Reflection on MLADU, Research Data, and the Bio-IT World Community
(5d)
With AWS Help, UK Group Moves Toward Global AMR Intelligence Platform
(1w)
CFDE Promotes Collaboration to Build Creative and Practical Solutions to Data Challenges during the Bio-IT Hackathon
(2w)
How Sugar on Brain Cells May Be Driving Alzheimer’s and How a Common Joint Supplement May Be Making It Worse
(2w)
Signal Management Isn’t Broken; It Simply Belongs to a Previous Era
(2w)
Network Effects: John Quackenbush on How Networks Illuminate Biology Beyond Gene Expression
(2w)
Insilico Medicine Launches Phase III Trial for AI-Developed Drug
(3w)
GEN News
Colorectal Cancer Targeted with Mass-Produced iPSC-Derived Allogeneic T Cells
(2d)
Oral Antiviral Blocks Measles-Like Virus Transmission in Ferrets
(2d)
Single-Cell Atlas Simultaneously Maps 3D Genome Architecture and DNA Methylation
(2d)
Single-Cell Maps Reveal Genome Reorganization in Alzheimer’s Brain Cells
(3d)
Autism-Like Traits in Mice Improved After Single Rapamycin Dose
(3d)
Turning Solar Power Into Protein
(3d)
Midlife Brain Aging Linked to Immune Cell Remodeling, Blood-Brain Barrier Decline
(3d)
Samsung Proposes Offer to Acquire Swiss CDMO Specializing in Peptides
(3d)
Transmissible Cancer Discovered in Freshwater Fish
(4d)
Transcripta Bio Raises $24M for AI-Driven Neurological Disease Therapies
(4d)
Cure Today
Why I Chose a Treatment Break After Years of Living With Stage 4 Ovarian Cancer
(1d)
When the Scan Is Over but the Waiting Begins: Living With Lymphoma Scanxiety
(2d)
RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
(2d)
Minimally Invasive Options in Rectal Cancer: TAMIS and Robotic Surgery
(3d)
Why I Don’t Want to Hear “You’ll Beat This” After a Metastatic Breast Cancer Diagnosis
(3d)
Diagnosed at 25 With Hodgkin's Lymphoma, She Says This Saved Her Life
(3d)
Cancer Care Leader Founds Program to Give Women Access to Cold Caps
(4d)
Choosing a Bra after a Mastectomy
(4d)
10 Things That Got Me Through Treatment ft. Edward Miskie
(5d)
The Healing Power of a Cancer Survivor Retreat During Scan Anxiety
(5d)
Contract Pharma
Asymchem Carbapenem API Site in China Successfully Completes First FDA Inspection
(2d)
Federal Equipment Announces Turnkey Sale of Denison Pharmaceuticals Facility
(2d)
Neurocrine Biosciences Names New Senior Vice Presidents
(2d)
The Friday Brief for July 24, 2026: M&A Activity Heating Up
(2d)
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer
(2d)
FDA Approves NSCLC Treatment Acquired by GSK in Nuvalent Deal
(3d)
BeOne Medicines Plans $300M NJ Expansion, Bringing US Manufacturing Investment Over $1B
(3d)
Bora and Onconic Ink Manufacturing Pact for US Acid Blocker Tablet Clinical Development
(3d)
Famar Names New CEO
(3d)
Cold Chain Technologies Launches EcoFlex XS Reusable Shipper
(3d)
Pharma Times
GSK wins US approval for ROS1 lung cancer therapy
(3d)
Lundbeck secures FDA Fast Track for narcolepsy drug
(3d)
R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
(4d)
Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
(4d)
Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
(5d)
ViiV Healthcare to unveil new HIV treatment data at AIDS 2026
(5d)
Jasper Therapeutics merges with Kira Pharmaceuticals
(6d)
EpilepsyGTx and ClearPoint Neuro join forces on targeted therapy
(1w)
NICE backs finerenone for heart failure
(2w)
EC approves Erbitux combination for first‑line treatment of BRAF V600E‑mutant mCRC
(2w)
Medcity News
Candid Health Snags $120M for AI RCM Platform
(9h)
Why Value-Based Care Only Works If You’ve Tamed Costs
(10h)
Medicine Understands Trauma’s Impact, But Rarely Asks About It
(10h)
A Prescription for Drug Costs: Inject Transparency and Improve Accessibility
(1d)
What Health Tech Investors Love in Founders — and What They Can’t Stand
(2d)
Priority Health Launches 2 Cancer Support Solutions with Color Health, Grail
(2d)
AI Will Reshape the Patient Experience
(2d)
Healthcare’s Next Source of Alpha Is Moving Upstream
(2d)
CRISPR Biotech Scribe Therapeutics Writes a New Chapter With $129M IPO
(2d)
Healthcare Investors Are Rewriting the ROI Playbook from Cost-Cutting to Cash Flow
(2d)
Chemical & Engineering News
Rudy Marcus, developer of electron transfer theory, dies at 102
(2d)
ACS continues 150th celebration at EuChemS
(2d)
Policy Watch: DHS puts new limit on international student stays in the US
(2d)
C&EN weekly chemistry news quiz, July 24
(2d)
Ethylene capacity keeps shrinking in South Korea and Japan as Chinese competition mounts
(3d)
Dow sales and profits balloon as polymer prices jump
(3d)
Team USA brings home gold from 58th International Chemistry Olympiad
(3d)
Uncovered: Record-setting laser boosts cryo-electron microscopy
(3d)
Direct sugar chemistry streamlines C-aryl glycoside synthesis
(3d)
George Christou wins 2026 Herty Medal
(3d)
The Pharma Letter
The week in pharma: action, reaction and insight – week to July 24, 2026
(13h)
Kaveri Therapeutics
(1d)
India’s pharma M&A market hits four-year high on blockbuster deals
(1d)
FDA approval for first-in-class in ADHD drug Simtriyo
(1d)
July 2026 EMA/CHMP medicines recommended for approval
(2d)
The next five years in bladder cancer: towards more predictive, personalized and less invasive care
(2d)
Merck & Co unveils early access strategy for once-monthly HIV prevention pill
(2d)
Lilly's retatrutide successful in two additional Phase III obesity trials
(2d)
Siegfried and Lonza lead four-way CDMO race in outsourced HPAPI
(2d)
Sanofi drops development of amlitelimab in atopic dermatitis
(2d)
Targeted Oncology
MCED Testing: Preparing for the Next Era of Cancer Risk Assessment
(8h)
Biomarkers Beyond High TMB or MMR-D May Be Needed for ICIs in Sarcomas
(11h)
Community Clinical Trials and the Lung Cancer Pipeline
(13h)
From Genetic Testing to Personalized Cancer Prevention
(1d)
Ethical Challenges Behind Genome Sequencing and Precision Medicine
(1d)
How Inherited BRCA Mutations Shape Breast Cancer's Genomic Behavior and Point Toward a New Treatment Paradigm
(1d)
Navigating CAR T Decision-Making in R/R DLBCL
(2d)
On-Body Injectors Point to At-Home Care, but Hurdles Remain in US
(2d)
Scaling Genetic Counseling in Community Oncology
(2d)
Changing ADC Choices for HR+/HER2–Breast Cancer
(2d)
MedWatch
Novo Nordisk's tablet sales continue to rise following a new subsidy scheme in the US
(2d)
Sanofi discontinues eczema treatment following strategic review
(2d)
Demant grew market share among US veterans in June
(2d)
The legal battle continues – Novo now seeks a temporary ban on Eli Lilly's advertisements
(2d)
Genmab fails to meet goals in Phase 3 cancer trial
(2d)
Novo Investors: Lawsuit against Eli Lilly is apt
(2d)
US lawyer on the Novo lawsuit: It's about changing public perception
(2d)
Leo Pharma to significantly scale back its Russian operations by 2027
(2d)
Johnson & Johnson reports positive data from clinical trial of bone marrow cancer treatment
(2d)
Analyst on Leo Pharma's operations in Russia: Bad for reputation
(3d)
In The Pipeline
Clinical Failure Rates Over the Decades: Yikes
(2d)
The Assault On Science Funding Continues
(3d)
Thoughts on the "Netflix Analogy"
(4d)
Benchmarking the Benchmarks
(5d)
More Pancreatic Cancer Vaccine Progress - Treatment and Preventative
(6d)
More Condensate Secrets Revealed
(1w)
The Battle For Sickle Cell
(2w)
Tau In the Clinic, Again
(2w)
Amyloidosis Continues to Fight Back
(2w)
Chemical Onshoring of All Kinds
(2w)
Pharmaphorum
Ipsen' Bylvay fluffs its lines in biliary atresia trial
(2d)
Sanofi gives up on amlitelimab in atopic dermatitis
(2d)
Re-rostered FDA committee backs peptide compounding
(2d)
J&J's multiple myeloma duo aces phase 3 trial
(2d)
Dexcom is first to join FDA/CMS health tech pilot
(3d)
Lilly plans Q1 2027 filing for obesity triple retatrutide
(3d)
EU clears AZ's SERD camizestrant, as FDA review drags on
(3d)
Nuvalent buy delivers new cancer approval for GSK
(3d)
As patents expire, fampridine is cleared for NHS use in MS
(3d)
Takeda gets first OK for orexin narcolepsy drug, in China
(3d)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(1mo)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(1mo)
Webinar: Learn how to accelerate the early stages of drug discovery
(1mo)
Therapy enables 89% survival rate in myeloma patients
(1mo)
Ulcerative colitis treatment shows best-in-class potential
(1mo)
UK patients to benefit from approval of weight loss tablet
(1mo)
Vertex presents new data on Casgevy in children
(1mo)
DDW Highlights: 16 June 2026
(1mo)
LXR inverse agonist shows promise in liver disease
(1mo)
Guide: One solution – from R&D, to QC
(1mo)
HIT Consultant
Medidata Launches Medidata Plus AI Layer to Standardize Clinical Trial Data and Workflows
(2d)
Wellumio Closes $9.75M to Commercialize Axana Portable Brain Imaging Device
(2d)
Cigna Healthcare Expands AI-Enabled Care Management to Reach 20% More Customers
(2d)
AdvancedMD Expands Waystar-Powered Revenue Cycle Offerings for Independent Practices
(2d)
Candid Health Secures $120M to Expand Autonomous Revenue Cycle Management Platform
(3d)
Karoo Health Secures $16.2M to Build Cardiovascular OS Infrastructure
(3d)
Prosper Medical Secures $16M for AI-Powered Primary Care Platform
(3d)
Teladoc Health Unveils Teladoc One to Deliver Connected, Adaptive Virtual Care
(3d)
Relatient Launches Clinical Request Automation Capability for Dash Voice AI Platform
(3d)
Assured Raises $19M to Replace Manual Credentialing with Autonomous AI Agents
(4d)
Insights: Pink Sheet
Peptide Industry Reaps Six Wins From RFK Jr.-Remade FDA Panel
(2d)
New ADVOCATE Analysis Backs Tavneos Efficacy, Amgen Tells US FDA In Withdrawal Dispute
(2d)
J&J’s Icotyde Nears EU Finish Line As First Oral IL-23 Receptor Drug For Plaque Psoriasis
(2d)
Second Time Lucky: Minoryx Wins EMA Backing For Nezglyal In cALD
(2d)
EMA Opens EU Door For New Cholesterol-Lowering Drugs From NewAmsterdam And LIB
(2d)
Five Days In December: Vanda Finally Gets Its Hetlioz Hearing
(2d)
GSK Gets EU Thumbs Up For Liver Drug Lynavoy After Success In US & UK
(2d)
Proveca To Challenge EMA Refusal For Ketamine Nasal Spray, Two Other Drugs Also Rejected
(2d)
New US FDA AdComm Members Provide Support For Peptides For Compounding
(2d)
US FDA Advisory Committee Will Revisit Rejection Of Sydnexis’ Pediatric Myopia Drug
(2d)
BioXconomy
SEC's semiannual reporting proposal debate continues
(2d)
Emerging IP trends for large molecules, CAR-T therapies, and biosimilars
(2d)
Royalty Pharma takes $425m interest in AZ’s cardiovascular drug
(2d)
Crystalys secures $130m to push gout treatment toward market
(3d)
Samsung Biologics makes bold peptide play with $1.8bn PolyPeptide buy
(3d)
Remote monitoring cuts CRA-CRC interaction
(3d)
Psychedelic renaissance continues as Jupiter Neurosciences licenses MDMA asset
(4d)
Earth's mightiest manufacturers: FDA pilot to supercharge US drug production
(4d)
Implementation science can help translate trial results into healthcare
(4d)
Jeremy Levin's message to Europe: This is your moment – if you choose to act
(4d)
BioCentury
Song among trio of new partners at Venrock
(2d)
Hub 101: Taiwan biotech looks to level up
(2d)
EMA’s CHMP backs two orphan drugs, rebuffs FDA-approved NPC therapy
(2d)
Scribe extends run of strong biotech IPO debuts: Public Equity Report
(2d)
Mapping AI giants’ bets across the biopharma tech stack
(3d)
Science Spotlight: Host-directed antivirals and a bivalent molecular glue
(3d)
Crossovers join Crystalys’ $130M series B: Venture Report
(3d)
Dosing, liver profile may differentiate Arrowhead in severe hypertriglyceridemia
(3d)
Initiate’s Owens on early funding and what it takes to be AI-native
(4d)
Former Black Diamond CEO David Epstein passes away
(4d)
SCRIP
Novo Nordisk Doubles Down On Efforts To Halt Lilly Tirzepatide Ads
(2d)
Merck Signs License Agreements For Monthly PrEP Drug Alimatravir In Developing Countries
(2d)
SMID Caps In The Buyer’s Seat
(2d)
Lundbeck Has Busy Spell Ahead For Readouts And Still Shopping For Gems
(2d)
Pipeline Watch: GSK Drops Camlipixant On Mixed CALM Data
(2d)
Sanofi Shelves Amlitelimab In Atopic Dermatitis After Pipeline Review
(2d)
Ipsen’s Bylvay Miss Shrinks Already-Sparse Biliary Atresia Pipeline
(2d)
As Cipla Chases US Milestone, gVentolin Scale-up Is Key
(2d)
With Jideytro Approval In NSCLC, GSK Has Another ‘Brick’ In Its Oncology Wall
(3d)
Lilly’s Retatrutide Continues To Show Strong Efficacy, But High Side Effects
(3d)